Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 7, 189–190 (1 March 2008) | doi:10.1038/nrd2545
Another blow for inhaled protein therapeutics
Abstract
The promise of an alternative to insulin injections for diabetes management suffered another disappointment on 15 January when Novo Nordisk discontinued the development of its fast-acting inhaled insulin product AERx iDMS, which was in Phase III development. Just 3 months before, on 18 October, Pfizer withdrew Exubera, the first approved inhaled human insulin powder and lung delivery device.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
